«Pfizer Inc.» Announced that terminates the study of the drug candidate, TRU-015, developed for the treatment of rheumatoid arthritis (RA) in collaboration with the biotechnology company «Trubion Pharmaceuticals Inc.». Decision «Pfizer» based on the preliminary results of phase IIb randomized, parallel, double-blind, placebo-controlled study to assess the efficacy and safety of two dosing regimens of the drug in combination with methotrexate in patients with RA, in which the TRU-015 did not reach the primary endpoint compared with placebo .
Free Viagra Samples
Cheap Viagra Online
Viagra How It Works
Viagra Cheap
Viagra Price
Buy Generic Viagra
Viagra Online Uk
Generic Viagra Brand Order
Cialis Cost Viagra Online
Viagra Shop Prices
Levitra Online Shop
Cialis Shop Medicine
Buy Levitra Online
Generic Levitra
Generic Viagra Canada
Buy Levitra
Levitra Pharmacy Canada Order
Viagra Prescription
Levitra 20mg
Cialis Levitra
This drug is well tolerated by patients, and serious side effects in the two groups took the drug were comparable with the group receiving placebo.
Commenting on this decision, senior vice president and chief medical director of «Trubion» Stromett Scott (Scott Stromatt) said that although the TRU-015 failed, now a drug company develops a new generation - SBI-087, which meets all required criteria.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.